BioNTech SE logo
BNTXBioNTech SE
Trade BNTX now
BioNTech SE primary media

About BioNTech SE

BioNTech (NASDAQ:BNTX), (FRA:22UA) is a biotechnology company focused on developing therapies for cancer and infectious diseases using its expertise in mRNA technology. Its most notable project has been the development and global distribution of the mRNA-based COVID-19 vaccine in partnership with Pfizer. Beyond its groundbreaking work on COVID-19, BioNTech is engaged in a broad range of projects aimed at harnessing the power of the immune system to fight disease. These projects include personalized cancer therapies, vaccines for infectious diseases, and treatments for other serious ailments. The objective of BioNTech is to create pioneering treatments that improve patient health and outcomes, leveraging its scientific expertise, and cutting-edge technology to push the boundaries of medicine.

What is BNTX known for?

Snapshot

Public US
Ownership
2008
Year founded
4239
Employees
Mainz, Germany
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

Products and/or services of BioNTech SE

  • COVID-19 vaccine in collaboration with Pfizer, providing significant global protection against the pandemic.
  • mRNA technology platform, innovating vaccine development and personalized cancer treatments.
  • Next-generation immunotherapies for treating cancer, utilizing the body's immune system to target and eliminate tumor cells.
  • Individualized cancer medicine development, focusing on creating therapies tailored to the unique genetic makeup of a patient's tumor.
  • RiboCytokines™, a novel class of mRNA-encoded therapeutics designed to precisely stimulate the immune system against cancer.
  • CAR-T cell therapies, developing engineered T cells to recognize and kill cancer cells specifically and effectively.

BioNTech SE executive team

  • Dr. Ugur Sahin M.D.Co-Founder, CEO & Chair of the Management Board
  • Dr. Ozlem Tureci M.D.Co-Founder, Chief Medical Officer & Member of Management Board
  • Dr. Sierk Poetting Ph.D.MD, COO & Member of Management Board
  • Dr. James Timothy Patrick Ryan Ph.D.Chief Legal & Business Officer and Member of the Management Board
  • Ms. Annemarie HanekampChief Commercial Officer & Member of Management Board
  • Mr. Ramon Zapata-GomezCFO & Member of Management Board
  • Ms. Lisa BirringerSenior Vice President of Global Financial Reporting & Accounting
  • Mr. Douglas Maffei Ph.D.Vice President of Strategy & Investor Relations
  • Jasmina AlatovicVice President Corporate Communications
  • Ms. Beate BernsSenior Vice President of Global Human Resources

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.